Herbalife is funding a two-year randomised trial at Ulster University of protein and micronutrient shakes for adults with obesity who are starting GLP-1 drugs, run inside PEACETIME, an EU-funded obesity programme for 9,000 people. For a company with EUR 4.6bn (US$5.0bn) in 2025 sales, the trial is a route to clinical evidence for its GLP-1 range. One of the named experts, Prof Carel le Roux, sits on Herbalife’s Nutrition Advisory Board.
At a glance
- 2 yearslength of the randomised trial in adults starting GLP-1 therapy (Herbalife; NutraIngredients)
- 9,000people PEACETIME will treat in Derry/Londonderry, Tyrone and Donegal (Ulster University; NutraIngredients)
- EUR 9.9MEU PEACEPLUS funding for PEACETIME (SEUPB; Ulster University gives EUR 10M)
- EUR 4.6bn(US$5.0bn) Herbalife net sales in 2025 (Herbalife results; Direct Selling News)
Trial and programme figures from Herbalife, Ulster University, SEUPB and NutraIngredients; sales as reported by Herbalife. EUR at the ECB reference rate of 19 November 2026. Checked 20 November 2026.
Herbalife announced the partnership in a Romanian release dated 15 November; NutraIngredients reported it on 19 November. The trial will test whether protein and micronutrient enriched shakes help with the low nutrient intake and muscle loss linked to GLP-1 drugs. Neither source gives the sample size, primary endpoint or Herbalife’s total contribution, and FoodEdge found no trial registry entry.
PEACETIME, led by Ulster, received EUR 9.9M under the EU PEACEPLUS programme, with the health departments of Ireland and Northern Ireland as match funders (SEUPB). It offers 12 months of community obesity care to 9,000 people in Derry/Londonderry, Tyrone and Donegal (Ulster University).
Herbalife names three experts: Prof Alex Miras, who leads PEACETIME, Dr Ruth Price and Prof Carel le Roux, described as a member of the Herbalife Nutrition Advisory Board. Herbalife announced his appointment in 2012 and lists him in its board roster.
The trial fits a range Herbalife already sells: its GLP-1 Nutrition Companion, combos built on its Formula 1 shake, launched in the US and Puerto Rico in February 2024. Herbalife reported 2025 net sales of EUR 4.6bn (US$5.04bn) (Herbalife; Direct Selling News).
FoodEdge view: Herbalife is buying evidence and access, so independence is what to check
Our reading is that Herbalife is buying a randomised trial in a publicly funded patient group that could back its GLP-1 range in Europe. That value holds only if the result is credible. A sponsor that funds the trial, with an adviser among the named experts, invites the question every buyer of that evidence will ask.
The due diligence question: are the endpoints and analysis plan registered before enrolment, who decides on publication if the shakes show no benefit, and how is le Roux’s Herbalife role managed?
Weighing a food biotech or nutrition deal? Independent technical due diligence, before you sign.
How we checked
- Sources: Herbalife release, 15 Nov 2026 (Romanian, FoodEdge translation); NutraIngredients, 19 Nov 2026; Ulster University, 17 Sep 2025; SEUPB; Herbalife 2012 release, board roster, 8 Feb 2024 release and 2025 results; Direct Selling News, 19 Feb 2026.
- Snapshot: 20 November 2026; EUR at the ECB reference rate of 19 November 2026 (US$1.0992).
- Key assumption: the Ulster trial is taken to run inside PEACETIME, as the company release and NutraIngredients describe it.
- Main limit: no registry entry, sample size, endpoints or funding total is public.
AI tools supported source research and drafting during the editorial process.


